TheranosticTrials.org

Clinical Trial · NCT01737112

99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients

Overview

This is an open-label SPECT/CT (single photon emission computed tomography / computed tomography) study to investigate the safety and diagnostic performance of 99mTc-3PRGD2 in evaluation of lung cancer patients. A single dose of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 ( ≤ 20 µg 3PRGD2) will be intravenously injected into the patients in suspicion of lung cancer. Visual and semiquantitative method will be used to assess the whole-body planar and thoracic SPECT/CT images. Any adverse events will be collected from the patients.

Sponsor

Peking Union Medical College Hospital

Phase

Early Phase 1

Contacts

Fang Li, MD (CONTACT)

lifang@pumch.cn

86-10-69155502

Zhaohui Zhu, MD (CONTACT)

zhu_zhaohui@yahoo.cn

86-10-69154196

Fang Li, MD (STUDY_CHAIR)

ClinicalTrials.gov

NCT01737112

Drug / Compound

3PRGD2

Isotope(s):
Target(s):
  • αvβ3
Ligand Class: Peptides
Chelator: HYNIC
Linker: PEG

Eligibility

Inclusion

  • Thoracic CT and/or 18F-FDG PET/CT diagnosis in suspicion of primary or recurrent lung cancer.
  • The lung cancer will be histologically confirmed or results of histology will be available.

Exclusion

  • Known severe allergy or hypersensitivity to IV radiographic contrast.
  • Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the Investigator, may significantly interfere with study compliance.